

B1  
COO't.  
human SCCE, which correspond to AAs 30-253 of the amino acid sequence shown in SEQ ID NO. 2; or the peptide shown in SEQ ID NO. 2. Presently preferred embodiments relate to transgenic mammals or mammalian embryos according to the invention, wherein the DNA sequence comprises the DNA shown in SEQ ID NO. 1 or the DNA sequence is SEQ ID NO:1.

---

Paragraph beginning at line 13 of page 22 has been amended as follows:

---

B2  
Figure 3A: Real time quantitative PCR analyses of recombinant human scce mRNA in various tissue preparations from the transgenic lines #1010 (black bars) and #107 (empty bars). Analyses in triplicate were carried out on RNA samples comprising pooled material from three animals from each line. The murine acidic ribosomal phosphoprotein P0 was used as internal standard. Mean and SD.

---

Paragraph beginning at line 19 of page 22 has been amended as follows:

---

B3  
Figure 3B ELISA-analyses of SCCE-protein in various tissues from the transgenic lines #1010 (black bars) and #107 (empty bars), and non-transgenic siblings (gray bars). Analyses in triplicate were carried out on pooled extracts from three animals from each line and controls. Mean and SD.

---

Paragraph beginning at line 32 of page 22 has been amended as follows:

---

B4  
Figure 4A: Immunoblot with SCCE-specific antibodies, reduced samples. Arrowheads denote, from top to bottom, glycosylated pro-SCCE, mixture of unglycosylated pro-SCCE and glycosylated SCCE, and unglycosylated SCCE. Amount of sample applied corresponding to 0.1 mg and 4.5 mg of skin for Tg and Wt, respectively.

---

Paragraph beginning at line 1 of page 23 has been amended as follows:

---

B5  
Figure 4B: Zymography in 12.5% acrylamide gel with 1%